SomaLogic, a US-based health-management platform developer backed by corporate investors Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics, has added $81m to a series A round now totalling $214m.
Casdin Capital is leading the round, with Janus Henderson Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures, Boston Millennia Partners and Millennium Management backing the latest tranche.
The first close included Farallon Capital Management, Foresite Capital, Blue Water Life Science Advisors, Madryn Asset Management, Fiscus Ventures, Reimagined Ventures, Monashee Investment Management, Mossrock Capital, Soleus Capital and funds and accounts advised by T. Rowe Price.
SomaLogic’s SomaScan tests are capable of measuring thousands of proteins from a single blood sample, and are intended to give users an idea of protein changes that can indicate susceptibility to a range of diseases.
Financial services firm Société Générale, Skye Associates, ProQuest Investments, New West Mezzanine and Lombard Odier provided $23m in series B funding for the company in 2000.
Laboratory services provider Quest Diagnostics invested an undisclosed amount in SomaLogic in 2005 and pharmaceutical company Otsuka did the same three years later. It subsequently secured $16.5m in a 2015 round featuring pharmaceutical firm Novartis.
The company completed a $200m round in early 2018 that included Nan Fung Life Sciences, part of conglomerate Nan Fung, in addition to digital health technology provider iCarbonX and Madryn Asset Management.
SomaLogic has now accumulated $578m in funding altogether. Cowen was placement agent for the series A extension while Reed Smith was legal adviser.
